Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S. Xenidis N, et al. Among authors: kotsakis a. Lung Cancer. 2010 Jun;68(3):450-4. doi: 10.1016/j.lungcan.2009.08.012. Epub 2009 Sep 23. Lung Cancer. 2010. PMID: 19783319 Clinical Trial.
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A. Koinis F, et al. Among authors: kotsakis a. Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16. Br J Cancer. 2017. PMID: 28510571 Free PMC article. Clinical Trial.
Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V. Milaki G, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18. Cancer Chemother Pharmacol. 2017. PMID: 28523597
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Pallis AG, Christofillakis Ch, Tselepatiotis E, Agelaki S, Vamvakas L, Souglakos J, Vardakis N, Kalykaki A, Kotsakis A, Argiraki A, Mavroudis D, Georgoulias V. Pallis AG, et al. Among authors: kotsakis a. Lung Cancer. 2007 Jan;55(1):101-7. doi: 10.1016/j.lungcan.2006.08.019. Epub 2006 Oct 17. Lung Cancer. 2007. PMID: 17049673 Clinical Trial.
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D. Apostolaki S, et al. Among authors: kotsakis a. Ann Oncol. 2007 May;18(5):851-8. doi: 10.1093/annonc/mdl502. Epub 2007 Feb 14. Ann Oncol. 2007. PMID: 17301075 Free article.
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group (HORG). Pallis AG, et al. Among authors: kotsakis a. Lung Cancer. 2008 Dec;62(3):356-63. doi: 10.1016/j.lungcan.2008.03.030. Epub 2008 May 22. Lung Cancer. 2008. PMID: 18501466
Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D. Georgoulias V, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344760 Clinical Trial.
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V. Kotsakis A, et al. Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23. Lung Cancer. 2015. PMID: 25662596 Clinical Trial.
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A; HORG’s Lung Cancer Working Group. Matikas A, et al. Among authors: kotsakis a. Cancer Chemother Pharmacol. 2016 Aug;78(2):369-76. doi: 10.1007/s00280-016-3094-7. Epub 2016 Jun 22. Cancer Chemother Pharmacol. 2016. PMID: 27335027 Clinical Trial.
215 results